Ras

Cat. No.

A63594

CAS No.

2648551-54-4

KRAS G12D inhibitor 10

KRAS G12D Inhibitor 10 is a selective inhibitor targeting the KRAS G12D mutation, a critical driver in various cancers. By inhibiting this variant, the compound demonstrates significant potential for research applications focused on KRAS G12D-mediated oncogenesis. Its role in disrupting the Ras signaling pathway makes it valuable for studies investigating cancer growth and therapeutic resistance mechanisms.

Cat. No.

A63595

CAS No.

2244904-69-4

(S)-BAY-293

(S)-BAY-293 serves as a negative control for the potent KRAS-SOS1 interaction inhibitor, BAY 293. This compound is utilized in experimental settings to validate the specificity and efficacy of BAY 293 in studying KRAS signaling pathways. Researchers can use (S)-BAY-293 to ensure experimental results are due to the intended inhibition and not off-target effects.

Cat. No.

A63597

CAS No.

2022986-61-2

KRAS inhibitor-6

KRAS inhibitor-6 is a potent inhibitor of the KRAS G12C mutation, specifically designed to selectively target and inhibit this oncogenic driver. Its mechanism of action involves binding to the active site of the mutant KRAS protein, effectively disrupting downstream signaling pathways involved in cellular proliferation and survival. This compound has significant implications for cancer research and therapeutic applications, particularly in the treatment of KRAS-driven tumors.

Cat. No.

A63598

CAS No.

2022986-70-3

KRAS inhibitor-8

KRAS inhibitor-8 is a selective inhibitor targeting the KRAS G12C mutation, known for its role in various cancers. This compound demonstrates significant biological activity by effectively disrupting KRAS signaling pathways, leading to reduced tumor growth in KRAS-driven malignancies. KRAS inhibitor-8 is ideal for research in cancer biology and drug discovery focused on mutant KRAS therapeutics.

Cat. No.

A63599

CAS No.

2022986-68-9

KRAS inhibitor-7

KRAS inhibitor-7 is a selective inhibitor targeting the KRAS G12C mutant protein. This compound demonstrates significant inhibition of KRAS G12C activity, making it a valuable tool for studying oncogenic signaling pathways involving KRAS mutations. Its primary applications include cancer research, particularly in the development of targeted therapies for KRAS-driven tumors.

Cat. No.

A63600

CAS No.

2642630-16-6

KRAS mutant protein inhibitor 1

KRAS mutant protein inhibitor 1 selectively targets and inhibits the activity of mutant KRAS proteins. Its primary mechanism involves disruption of KRAS-mediated signaling pathways, which are critical in various cancers. This compound is valuable for research applications focused on understanding the role of KRAS mutations in tumorigenesis and exploring potential therapeutic strategies for KRAS-driven malignancies.

Cat. No.

A63601

CAS No.

2756739-00-9

KRAS G12C inhibitor 32

KRAS G12C Inhibitor 32 is a potent inhibitor targeting the KRAS G12C mutation. This eight-membered heterocyclic compound demonstrates strong inhibitory activity, which is critical for studies focusing on cancer therapeutics associated with KRAS mutations. It is primarily utilized in research exploring the mechanisms of KRAS-driven malignancies and the development of targeted therapies.

Cat. No.

A63602

CAS No.

2706637-43-4

(Rac)-D3S-001

(Rac)-D3S-001 is a racemic mixture of the compound D3S-001, which serves as a potent modulator of specific biological pathways. This compound exhibits significant activity in regulating cellular processes, making it a valuable tool for investigating the underlying mechanisms of disease. It is particularly useful in pharmacological studies and in the development of therapeutic strategies targeting related biological systems.

Cat. No.

A63603

CAS No.

2648584-51-2

KRAS G12C inhibitor 27

KRAS G12C inhibitor 27 is a potent inhibitor targeting the KRAS G12C mutant protein, which plays a pivotal role in various cancers. This compound exhibits significant antitumor activity, making it a valuable tool for research in cancer biology and therapeutic development. Its application extends to studying KRAS-driven tumors and evaluating the efficacy of targeted therapies.

Cat. No.

A63605

CAS No.

2757095-11-5

KRAS G12D inhibitor 3

KRAS G12D inhibitor 3 is a selective inhibitor targeting the KRAS G12D mutant with an IC50 of less than 500 nM. It exhibits significant antitumor activity, making it relevant for cancer research focused on KRAS-driven tumors. Additionally, this compound functions as a click chemistry reagent, featuring an alkyne group that enables copper-catalyzed azide-alkyne cycloaddition with azide-containing molecules, facilitating various bioconjugation applications in molecular biology.

Cat. No.

A63606

CAS No.

2946593-43-5

G12Si-2

G12Si-2 is an analog of G12Si-1 that serves as a negative control in research applications. It acts as a non-covalent inhibitor specifically for the G12S mutant of K-Ras. This compound is valuable for studies aimed at elucidating the mechanisms of K-Ras signaling and evaluating the effects of various inhibitors in cellular contexts.

Cat. No.

A63607

CAS No.

2649788-45-2

KRAS G12C inhibitor 18

KRAS G12C inhibitor 18 is a selective inhibitor targeting the KRAS G12C mutation. This compound exhibits significant anti-tumor activity, making it valuable for cancer research focused on KRAS-driven malignancies. It is suitable for studies investigating the therapeutic potential of KRAS inhibition in oncogenesis and treatment resistance.

Cat. No.

A63608

CAS No.

2411786-32-6

KRAS inhibitor-20

KRAS Inhibitor-20 is a small molecule inhibitor targeting the oncogenic mutant KRasG12C. It demonstrates potent inhibitory activity with an IC50 value of less than 10 nM, making it an effective tool for studying KRas-driven malignancies. This compound is valuable for research applications focused on cancer biology, offering insights into therapeutic strategies for KRas-related tumors.

Cat. No.

A63609

CAS No.

2230873-67-1

KRAS inhibitor-16

KRAS Inhibitor-16 is a selective inhibitor targeting the KRAS G12C mutation, demonstrating a potent activity with an IC50 of 0.457 µM. This compound effectively inhibits phosphorylated ERK in MIA PaCA-2 and A549 cell lines, with IC50 values of 3.06 µM and 11.1 µM, respectively. KRAS Inhibitor-16 is suitable for research applications focusing on pancreatic, colorectal, and lung cancers, contributing to the advancement of targeted therapies in these malignancies.

Cat. No.

A63610

CAS No.

2374152-69-7

KRAS inhibitor-4

KRAS inhibitor-4 (compound F12) is a potent inhibitor targeting KRAS, a critical regulator of cell signaling pathways. This compound exhibits significant anticancer activity by disrupting KRAS-mediated signaling, thereby inhibiting tumor growth and proliferation. It is a valuable tool for research focused on cancer biology and therapeutic development related to KRAS mutations.

Cat. No.

A63611

CAS No.

2230873-78-4

KRAS inhibitor-14

KRAS Inhibitor-14 is a selective inhibitor targeting the KRAS G12C mutation, exhibiting a potent IC50 of 0.249 µM. It effectively inhibits phosphorylated ERK (p-ERK) with IC50 values of 1.12 µM in MIA PaCA-2 cells and >33.3 µM in A549 cells. This compound is valuable for investigating therapeutic strategies in pancreatic, colorectal, and lung cancers.

Cat. No.

A63613

CAS No.

847337-63-7

KRAS G12C inhibitor 29

KRAS G12C inhibitor 29 is a selective inhibitor targeting the KRAS G12C mutation, which plays a critical role in various cancer types. This compound demonstrates significant activity in suppressing tumor growth in KRAS G12C-driven models, making it a valuable tool for cancer research. It is particularly useful for studies focused on understanding KRAS-related signaling pathways and developing targeted therapies.

Cat. No.

A63614

CAS No.

23665-96-5

Neogrifolin

Neogrifolin is a selective inhibitor of KRAS, which plays a critical role in the signaling pathways associated with cancer cell proliferation and survival. This compound has demonstrated significant anti-cell viability activity against human cancer cell lines, including HeLa (IC50: 24.3 μM), SW480 (IC50: 34.6 μM), and HT29 (IC50: 30.1 μM). Neogrifolin is primarily utilized in research applications aimed at elucidating the role of KRAS in tumorigenesis and investigating potential therapeutic strategies for KRAS-driven malignancies.

Cat. No.

A63615

CAS No.

5335-97-7

NSC1011

NSC1011 is a selective inhibitor of Ras converting enzyme 1 (Rce1), demonstrating an IC50 of 6.9 µM against the human Rce1. This compound disrupts the localization of key Ras proteins, including EGFR-H-Ras, EGFR-N-Ras, and EGFR-K-Ras. NSC1011 is valuable for research on Ras signaling pathways and their implications in cancer biology.

Cat. No.

A63616

CAS No.

3024991-82-7

K-Ras-IN-3

K-Ras-IN-3 is a selective inhibitor of GDP-bound K-Ras G12V, exhibiting an IC50 value of 0.371 nM. This compound demonstrates significant potential for cancer research, particularly in the study of K-Ras-driven tumors and their associated signaling pathways. Its specificity enables investigations into K-Ras's role in oncogenesis and therapy resistance.

Cat. No.

A63617

CAS No.

3085516-79-3

KRAS G12C-IN-74

KRAS G12C-IN-74 is a selective inhibitor of KRAS G12C with a target IC50 of 43.18 nM. This compound induces G0/G1 cell cycle arrest and promotes apoptosis specifically in KRAS G12C-mutated cancer cells. It is suitable for research applications focusing on KRAS G12C-driven pancreatic, colorectal, and lung cancers.

Cat. No.

A63619

CAS No.

663941-66-0

8-CPT-cAMP-AM

Synonyms: 8-(4-Chlorophenylthio)-cAMP-AM

8-CPT-cAMP-AM is a membrane-permeant analogue of cyclic adenosine monophosphate (cAMP) that acts as an activator of cAMP- and cGMP-dependent protein kinases. It also stimulates exchange protein directly activated by cAMP (Epac), making it a valuable tool for investigating cAMP signaling pathways. This compound is useful in research applications studying cellular processes influenced by cAMP, such as cell proliferation, differentiation, and effects on various physiological responses.

Cat. No.

A63620

CAS No.

3033565-36-2

pan-KRAS-IN-6

pan-KRAS-IN-6 is a highly potent pan-KRAS inhibitor, exhibiting IC50 values of 9.79 nM for Kras G12D and 6.03 nM for Kras G12V. This compound effectively targets KRAS mutant forms associated with various cancers, making it a valuable tool for studying KRAS signaling pathways and evaluating therapeutic strategies in KRAS-driven tumors. Its specificity and efficacy position it as a key reagent in cancer research and drug discovery efforts targeting KRAS-related malignancies.

Cat. No.

A63621

CAS No.

2737269-61-1

KRAS G12C inhibitor 21

KRAS G12C inhibitor 21 is a selective inhibitor targeting the KRAS G12C oncogene. It effectively disrupts downstream signaling pathways associated with cell proliferation and survival in KRAS-driven malignancies. This compound is primarily utilized in cancer research to explore therapeutic strategies for malignancies harboring KRAS G12C mutations.

Cat. No.

A63622

CAS No.

2241720-04-5

KRAS G12C inhibitor 37

KRAS G12C inhibitor 37 is a selective inhibitor targeting the KRAS G12C mutation, a key driver in various cancers. This compound displays significant efficacy in disrupting KRAS-mediated signaling pathways, thus impeding tumor growth and proliferation. KRAS G12C inhibitor 37 is intended for research applications focused on elucidating the therapeutic potential in KRAS G12C-driven malignancies.